Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07AOO
|
||||
| Former ID |
DCL000626
|
||||
| Drug Name |
Rilotumumab
|
||||
| Drug Type |
Antibody
|
||||
| Company |
Amgen
|
||||
| Target and Pathway | |||||
| Target(s) | Hepatocyte growth factor | Target Info | [536533], [550250] | ||
| Pathway Interaction Database | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | ||||
| Arf6 signaling events | |||||
| Signaling events mediated by TCPTP | |||||
| Direct p53 effectors | |||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||||
| Syndecan-1-mediated signaling events | |||||
| Stabilization and expansion of the E-cadherin adherens junction | |||||
| FGF signaling pathway | |||||
| References | |||||
| Ref 542900 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7986). | ||||
| Ref 547311 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015060) | ||||
| Ref 536533 | AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6735-42. | ||||
| Ref 550250 | Clinical pipeline report, company report or official report of Amgen (2009). | ||||